{
    "nct_id": "NCT04613518",
    "official_title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis",
    "inclusion_criteria": "* Confirmed diagnosis of ulcerative colitis (UC) at least 3 months' duration prior to screening\n* Moderately to severely active UC as assessed by the modified Mayo score\n* Documentation of an inadequate response, loss of response, or intolerance to a treatment course of 1 or more of the following standard of care medications: oral 5-aminosalicylic acids, corticosteroids, immunomodulators, anti-tumor necrosis factor (TNF) agents, integrin inhibitors[SA1]\n* Documentation of prior treatment with corticosteroids for â‰¥ 4 weeks\n* Males and females must agree to follow specific methods of contraception, if applicable\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Current diagnosis of Crohn's disease (CD) or diagnosis of indeterminate colitis (IC), ischemic colitis, or pseudomembranous colitis\n* Current evidence of fulminant colitis, abdominal abscess, toxic megacolon, or bowel perforation\n* History or evidence of any extensive colonic resection, or subtotal or total colectomy\n* Women who are pregnant or breastfeeding\n* Prior exposure to BMS-986165 or a tyrosine kinase 2 (TYK2) inhibitor\n\nOther protocol-defined inclusion/exclusion criteria apply.",
    "miscellaneous_criteria": ""
}